Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
作者信息
Walter H, Thomas A L
出版信息
Br J Cancer. 2013 Jun 25;108(12):2417-8. doi: 10.1038/bjc.2013.244.
Abstract
摘要
相似文献
1
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.FOLFOXIRI联合贝伐单抗治疗后的肝切除术：详细病理回顾
Br J Cancer. 2013 Jun 25;108(12):2417-8. doi: 10.1038/bjc.2013.244.
2
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.贝伐单抗治疗结直肠癌患者期间的晚期吻合口裂开
Clin Oncol (R Coll Radiol). 2011 Sep;23(7):497-8. doi: 10.1016/j.clon.2011.03.009. Epub 2011 May 14.
3
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.接受 FOLFOXIRI 联合贝伐珠单抗治疗的结直肠癌肝转移患者的组织病理学评估。
Br J Cancer. 2013 Jun 25;108(12):2549-56. doi: 10.1038/bjc.2013.245. Epub 2013 May 23.
4
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.转移性结直肠癌的 FOLFOXIRI 和贝伐珠单抗初始治疗。
N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
5
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.FOLFOXIRI 或 FOLFOXIRI 联合贝伐珠单抗作为转移性结直肠癌一线治疗：来自两项随机临床试验的倾向评分调整分析。
Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
6
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.贝伐珠单抗联合 FOLFOXIRI 方案治疗晚期结直肠癌患者：两项新临床试验（CHARTA 和 PERIMAX）介绍及文献复习。
BMC Cancer. 2012 Aug 16;12:356. doi: 10.1186/1471-2407-12-356.
7
[Systemic therapy for colorectal cancer].[结直肠癌的全身治疗]
Chirurg. 2005 Jun;76(6):570-2, 574. doi: 10.1007/s00104-005-1038-6.
8
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.一项比较术前化疗联合贝伐珠单抗与术后化疗联合贝伐珠单抗用于可直接切除的肝转移性结直肠癌患者的随机 II 期研究。
Clin Colorectal Cancer. 2020 Sep;19(3):e140-e150. doi: 10.1016/j.clcc.2020.03.004. Epub 2020 Apr 2.
9
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.新辅助化疗联合和不联合贝伐珠单抗治疗结直肠癌肝转移的围手术期并发症。
J Gastrointest Surg. 2013 Mar;17(3):527-32. doi: 10.1007/s11605-012-2108-y. Epub 2013 Jan 9.
10
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.FOLFOXIRI 联合贝伐珠单抗作为 BRAF 突变转移性结直肠癌的一线治疗。
Eur J Cancer. 2014 Jan;50(1):57-63. doi: 10.1016/j.ejca.2013.08.024. Epub 2013 Oct 15.
引用本文的文献
1
Missing colorectal liver metastases: the surgical challenge.结直肠肝转移瘤的外科治疗挑战
Langenbecks Arch Surg. 2021 Nov;406(7):2163-2175. doi: 10.1007/s00423-021-02297-4. Epub 2021 Sep 30.
2
Managing Synchronous Liver Metastases in Colorectal Cancer.结直肠癌同步肝转移的管理
Indian J Surg Oncol. 2018 Dec;9(4):461-471. doi: 10.1007/s13193-018-0765-3. Epub 2018 May 18.
3
Strategies for Management of Synchronous Colorectal Metastases.同时性结直肠转移瘤的管理策略
Curr Surg Rep. 2014 Jun 1;2:62. doi: 10.1007/s40137-014-0062-1.
本文引用的文献
1
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.接受 FOLFOXIRI 联合贝伐珠单抗治疗的结直肠癌肝转移患者的组织病理学评估。
Br J Cancer. 2013 Jun 25;108(12):2549-56. doi: 10.1038/bjc.2013.245. Epub 2013 May 23.
2
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.贝伐珠单抗联合 FOLFOXIRI（伊立替康、奥沙利铂、氟尿嘧啶和亚叶酸）作为转移性结直肠癌一线治疗：一项 2 期试验。
Lancet Oncol. 2010 Sep;11(9):845-52. doi: 10.1016/S1470-2045(10)70175-3. Epub 2010 Aug 9.
3
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗：抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
4
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.一种使用动态对比增强磁共振成像监测肿瘤治疗的简单、可重复的方法。
Br J Cancer. 2006 May 22;94(10):1420-7. doi: 10.1038/sj.bjc.6603140.
Zotero 插件